Efficacy of Pharmaceutical-grade Chondroitin sulfate in symptomatic knee osteoarthritis

Primary tabs

NEWS
Efficacy of Pharmaceutical-grade Chondroitin sulfate in symptomatic knee osteoarthritis

Reginster JY and colleagues in their latest study showed that 800 mg/day pharmaceutical-grade Chondroitin Sulfate (CS) is more efficacious than placebo and similar to celecoxib in reducing pain and improving function over six months in symptomatic knee osteoarthritis (OA) patients. The investigators recommend this formulation of CS as a first-line treatment for knee OA.

OA is a prevalent musculoskeletal condition causing pain, loss of function and disability. According to the latest guidelines, maintenance therapy should be conducted with symptomatic slow-acting drugs for OA, a class of drugs that offers a high degree of safety and tolerability

The 6-month prospective, randomized, double-blind, double-dummy study was conducted to establish the efficacy of Pharmaceutical grade CS in the management of symptomatic knee osteoarthritis in accordance with the European Medicines Agency guideline. The patients were assigned to either of the following three groups: 1. Group CS: one tablet of CS 800 mg and one capsule of placebo celecoxib; 2. Group celecoxib: one tablet of placebo CS and one capsule of celecoxib 200 mg; 3. Group placebo: one tablet of placebo CS and one capsule of placebo celecoxib. The primary endpoints were changes in pain on a Visual Analogue Scale (VAS) and in the Lequesne Index (LI). The secondary endpoints were Minimal-Clinically Important Improvement (MCII) and Patient-Acceptable Symptoms State (PASS).

The result estimated that 604 patients (knee osteoarthritis) diagnosed according to American College of Rheumatology (ACR) criteria, recruited in five European countries and followed for 182 days. CS and celecoxib showed a greater significant reduction in pain and LI than placebo. In the intention-to-treat (ITT) population, pain reduction in VAS at day 182 in the CS group (-42.6 mm) and in celecoxib group (-39.5 mm) was significantly greater than the placebo group (-33.3 mm) (p=0.001 for CS and p=0.009 for celecoxib), while no variation was observed between CS and celecoxib. A similar trend was noted for the LI, as the reduction in this metric in the CS group (-4.7) and celecoxib group (-4.6) was significantly greater than the placebo group (-3.7) (p=0.023 for CS and p=0.015 for celecoxib), no difference was observed between CS and celecoxib. Both secondary endpoints (MCII and PASS) at day 182 improved significantly in the CS and celecoxib groups. All treatments demonstrated excellent safety profiles.

Source:

Ann Rheum Dis. 2017 May 22.

Link to the source:

https://www.ncbi.nlm.nih.gov/pubmed/28533290

The original title of the article:

Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus Celecoxib versus Placebo Trial (CONCEPT).

Authors

Reginster JY, Dudler J, et al.

SearchTags: 
Pharmaceutical grade Chondroitin sulfate, Celecoxib, Symptomatic knee osteoarthritis, Anti-inflammatory, NSAIDs, Prospective randomized double-blind double-dummy study, Efficacy, Visual Analogue Scale, Lequesne Index, Minimal-Clinically Important Improvement, Patient-Acceptable Symptoms State, Oral

Comments

Log in or register to post comments